Mangoceuticals Inc (NASDAQ:MGRX)’s traded shares stood at 71619.0 during the last session, with the company’s beta value hitting 2.39. At the close of trading, the stock’s price was $1.49, to imply a decrease of -1.97% or -$0.03 in intraday trading. The MGRX share’s 52-week high remains $7.66, putting it -414.09% down since that peak but still an impressive 11.41% since price per share fell to its 52-week low of $1.32. The company has a valuation of $15.86M, with an average of 0.17 million shares in intraday trading volume over the past 10 days and average of 262.63K shares over the past 3 months.

Mangoceuticals Inc (NASDAQ:MGRX) trade information

After registering a -1.97% downside in the last session, Mangoceuticals Inc (MGRX) has traded red over the past five days. The 5-day price performance for the stock is -17.22%, and -29.05% over 30 days. With these gigs, the year-to-date price performance is -69.62%. Short interest in Mangoceuticals Inc (NASDAQ:MGRX) saw shorts transact 0.12 million shares and set a 0.56 days time to cover.

MGRX Dividends

Mangoceuticals Inc has its next earnings report out in August. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Mangoceuticals Inc (NASDAQ:MGRX)’s Major holders

Mangoceuticals Inc insiders hold 27.82% of total outstanding shares, with institutional holders owning 0.66% of the shares at 0.91% float percentage. In total, 0.66% institutions holds shares in the company.

We also have Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Total Market Index Fund as the top two Mutual Funds with the largest holdings of the Mangoceuticals Inc (MGRX) shares. Going by data provided on Apr 30, 2025, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund holds roughly 10.54 shares. This is just over 0.10% of the total shares, with a market valuation of $15700.0. Data from the same date shows that the other fund manager holds a little less at 3.25, or 0.03% of the shares, all valued at about 4835.0.